Abstracts tagged "pain"

Abstract Number: 1064 • ACR Convergence 2024
Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center
Shannon Herndon¹, Jack Kimball¹ and David Leverenz², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Palliative medicine prioritizes quality of life and relief of suffering in serious illness. Despite high morbidity and mortality in rheumatic disease, data suggests that…
Abstract Number: 1215 • ACR Convergence 2024
Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen
Maria Intriago¹, Puran Nepal², Laura L. Daniel¹, Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Adriana M. Hung⁴ and Cecilia P. Chung¹, ¹University of Miami, Miami, FL, ²Vanderbilt University Medical Center, Vanderbilt, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Cyclobenzaprine is a commonly-used centrally-acting muscle relaxant; it has been approved for short-term treatment of muscle spasms associated with acute musculoskeletal pain despite limited…
Abstract Number: 1474 • ACR Convergence 2024
Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Christopher Ritchlin¹, Ennio Lubrano², Maria Sole Chimenti³, Evan Leibowitz⁴, Mohamed Sharaf⁵, Oyediran Adelakun⁶, Emmanouil Rampakakis⁷, Francois Nantel⁸, Frederic Lavie⁹ and Atul Deodhar¹⁰, ¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ³Rheumatology, Allergology and Clinical Immunology, System Medicine Department, University of Rome Tor Vergata, Rome, Italy, ⁴Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁶Janssen Research & Development, LLC, Titusville, NJ, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Nantel Medsci Consult, Montreal, QC, Canada, ⁹Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹⁰Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In previous DISCOVER (D)1 and 2 analyses, the fully human IL-23p19-subunit inhibitor guselkumab (GUS) was associated with robust and sustained improvement in PsA signs/symptoms…
Abstract Number: 2101 • ACR Convergence 2024
Patient Characteristics Associated with Objectively-Assessed Physical Activity in Veterans with Knee Osteoarthritis
Hannah Brubeck¹, David Azizi², Sarah Wetzel², Marianna Olave², Rachel Gillcrist³, Bridget Kramer⁴, Bibiana Ateh⁵, Daniel White⁶, Carla Scanzello⁷, Tuhina Neogi⁸, Alexis Ogdie⁹, Bryant England⁴, Mercedes Quinones¹⁰, Katherine Wysham¹¹ and Joshua Baker⁷, ¹VA Puget Sound Health Care System, Seattle, WA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Washington DC VA Medical Center, Washington, DC, ⁶University of Delaware, Newark, DE, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁰Washington DC VA Medical Center, Bethesda, MD, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Despite strong recommendations for physical activity in knee osteoarthritis (KOA) clinical practice guidelines, only a small fraction of those with KOA meet guidelines for…
Abstract Number: PP06 • ACR Convergence 2024
Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Since receiving my rheumatoid arthritis (RA) diagnosis in 2015, I have found that one of my top five strategies to manage my symptoms is spending…
Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
George Spencer-Green¹, David Hunter², Thomas Schnitzer³, Sheue-Fang Shih⁴, Tien-Tzu Tai⁴, Cathy Kao⁴ and Siao-Ning Huang⁴, ¹Taiwan Liposome Company, Cambridge, MA, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Taiwan Liposome Company, Taipei, Taiwan (Republic of China)
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
Abstract Number: 0413 • ACR Convergence 2023
Transcriptomic Analysis of Peripheral Blood Mononuclear Cells Reveals Pain and Inflammation Specific Alterations in Difficult-to-treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gábor Sütő², Gábor Kumánovics³, József Kun⁴, Péter Urbán⁵, Attila Gyenesei⁵, Panna Királyhidi⁶, Georg Schett⁷, György Nagy⁸ and Zsuzsanna Helyes⁹, ¹Department of Pharmacology and Pharmacotherapy, University of Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Budapest, Hungary, ²Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, ³Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary, ⁴Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Budapest, Hungary, ⁵Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁶Department of Genetics, Cell- and Immunobiology, Semmelweis University School of Medicine, Budapest, Hungary, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Department of Rheumatology and Clinical Immunology, Semmelweis University School of Medicine; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, ⁹Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Pécs, Hungary; National Laboratory for Drug Research and Development, Pécs, Hungary
Background/Purpose: Despite novel treatment strategies in rheumatoid arthritis (RA), approximately 20-30% of patients remain symptomatic. The EULAR definition of difficult-to-treat (D2T) RA has recently been…
Abstract Number: 0865 • ACR Convergence 2023
Reactive Oxygen Species-scavenging Nanoparticles Target Macrophage Polarization for Osteoarthritis Therapy
Caifeng Deng¹, Yongbing Xiao², Xuan Zhao¹, Hui Li², Yuxiao Chen¹, Chao Zeng² and Guanghua Lei², ¹Xiangya Hospital, Changsha, China, ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Unbalanced M1/M2 polarization of synovial macrophages plays vital roles in the symptomatic and structural progression of osteoarthritis (OA). The accumulation of intracellular reactive oxygen…
Abstract Number: 1290 • ACR Convergence 2023
Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis
Katie McMenamin¹, Kristin Wipfler², Austin Wheeler³, Grant Cannon⁴, K Wysham⁵, Brian Sauer⁶, Bryant England³, Kaleb Michaud³, Ted R Mikuls⁷ and Joshua Baker⁸, ¹Boston University, Boston, MA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
Abstract Number: 1812 • ACR Convergence 2023
Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain
Laura Daniel¹, Alyson Dickson², Puran Nepal¹, Otis Wilson³, Adriana Hung², Dale Plummer³, William Dupont³, Katherine Murray³, C. Michael Stein², Wayne Ray³ and Cecilia Chung⁴, ¹University of Miami, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴University of Miami, Miami, FL
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved by the FDA for the treatment of different forms of chronic pain. Because of its adrenergic activity,…
Abstract Number: 1982 • ACR Convergence 2023
Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis
Terence O'Neill¹, Matthew Parkes¹, Michael Bowes², Richard Hodgson¹ and David Felson³, ¹University of Manchester, Manchester, United Kingdom, ²Imorphics, Manchester, United Kingdom, ³Boston University, Boston, MA
Background/Purpose: There are currently no licensed therapies which reduce progression of knee OA. Current therapies focus on reducing pain, have limited effect, and some have…
Abstract Number: 2525 • ACR Convergence 2023
Comparing Patellar Tendon Characteristics Between Adults with and Without Knee Pain
Samantha Price¹, Karin Silbernagel², David Felson³, Joshua Stefanik⁴ and Patrick Corrigan¹, ¹Saint Louis University, St. Louis, MO, ²University of Delaware, Avondale, PA, ³Boston University, Boston, MA, ⁴Northeastern University, Boston, MA
Background/Purpose: Knee pain is one of the most common types of joint pain leading to disability, limited physical activity, and reduced quality of life. While…
Abstract Number: 0429 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Andrew Garrison⁶, Yanna Song⁶, Sara K. Penn⁶, Ralph Lippe⁷, Diane Caballero⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Inc., Chicago, IL, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
Abstract Number: 0867 • ACR Convergence 2023
Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis
Ravi Krishnan¹, Catherine Stapledon², Christian Reiter², Stewart Ryan³, Sebastien Bauquier³ and Thierry Beths³, ¹Paradigm Biopharmaceuticals, Adelaide, Australia, ²Paradigm Biopharmaceuticals, Melbourne, Australia, ³U-Vet Werribee Animal Hospital, University of Melbourne, Melbourne, Australia
Background/Purpose: Pentosan Polysulfate sodium (PPS) is a semi-synthetic polysaccharide and a glycosaminoglycan mimetic. The multiple actions of PPS involve anti-inflammatory effects via inhibition of NF-κB;…
Abstract Number: 1330 • ACR Convergence 2023
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial
John Lampa¹, Dan Nordstrom², Ronald van Vollenhoven³, Merete Hetland⁴, Espen A Haavardsholm⁵, Mikkel Østergaard⁶, Anna Rudin⁷, Marte Schrumpf Heiberg⁵, Michael Nurmohamed³, Bjorn Gudbjornsson⁸, Kristina Lend⁹, Kim Hørslev-Petersen¹⁰, Tuulikki Sokka-Isler¹¹, Gerdur Maria Grondal¹², Simon Krabbe¹³, Joakim Lindqvist¹⁴, Anna-Karin Hultgård Ekwall¹⁵, Daniel Glinatsi¹⁶, Meliha Kapetanovic¹⁷, Cidem Gentline¹⁴, Anna-Birgitte Aga¹⁸, Heikki Relas², Tove Lorenzen¹⁹, Giovanni Cagnotto²⁰, Johan Back²¹, Oliver Hendricks²², Bas Dijkshoorn²³, Kajsa Öberg²⁴, Maud-Kristine Aga Ljoså²⁵, Eli Brodin²⁶, Hanne Merete Lindegaard²⁷, Annika Söderbergh²⁸, Milad Rizk²⁹, Alf Kastbom³⁰, Per Larsson³¹, Line Uhrenholt³², Søren Just³³, David J Stevens³⁴, Trine B Laurberg³⁵, Gunnstein Bakland³⁶, Inge Olsen³⁷, Joseph Sexton¹⁸ and Till Uhlig¹⁸, ¹Stockholm County, Hãsselby, Sweden, ²Helsinki University Hospital, Helsinki, Finland, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁸Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹⁰University of Southern Denmark, Odense, Denmark, ¹¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹³Herlev-Gentofte University Hospital, Herlev, Denmark, ¹⁴Karolinska University Hospital, Stockholm, Sweden, ¹⁵Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, ¹⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, ¹⁷Lund University and Skåne University Hospital, Lund, Sweden, ¹⁸Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Silkeborg University Hospital, Silkeborg, Denmark, ²⁰Skåne University Hospital, Lund, Sweden, ²¹Uppsala University Hospital, Uppsala, Sweden, ²²Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²³Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, ²⁴Falu Hospital, Falun, Sweden, ²⁵Ålesund Hospital, Ålesund, Norway, ²⁶Haukeland University Hospital, Bergen, Norway, ²⁷Odense Hospital, Odense, Denmark, ²⁸Örebro University Hospital, Örebro, Sweden, ²⁹Västmanlands Hospital Västerås, Västerås, Sweden, ³⁰Linköping University, Linköping, Sweden, ³¹Academic Specialist Center, Stockholm, Sweden, ³²Aalborg University Hospital, Aalborg, Denmark, ³³Section of Rheumatology, Department of Medicine, Odense University Hospital – Svendborg Hospital, Odense, Denmark, ³⁴St. Olavs Hospital, Trondheim, Norway, ³⁵Aarhus University Hospital, Aarhus, Denmark, ³⁶University Hospital of North Norway, Tromsø, Norway, ³⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established. Methods: In this investigator-initiated, randomized, open-label study (NCT01491815), patients with…

« Previous Page
1
…
5
6
7
8
9
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].